Cargando…

Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience

Background: Large epidemiological studies describing the trends in incidence rates and mortality of synchronous brain metastases (SBMs) are lacking. The study aimed to provide a comprehensive understanding of the changes in the incidence and mortality of SBMs over the previous ten years. Methods: Tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Che, Wenqiang, Liu, Jie, Fu, Tengyue, Wang, Xiangyu, Lyu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689090/
https://www.ncbi.nlm.nih.gov/pubmed/36354720
http://dx.doi.org/10.3390/curroncol29110660
_version_ 1784836438368452608
author Che, Wenqiang
Liu, Jie
Fu, Tengyue
Wang, Xiangyu
Lyu, Jun
author_facet Che, Wenqiang
Liu, Jie
Fu, Tengyue
Wang, Xiangyu
Lyu, Jun
author_sort Che, Wenqiang
collection PubMed
description Background: Large epidemiological studies describing the trends in incidence rates and mortality of synchronous brain metastases (SBMs) are lacking. The study aimed to provide a comprehensive understanding of the changes in the incidence and mortality of SBMs over the previous ten years. Methods: Trends in the incidence of solid malignancies outside of the CNS in patients with SBMs and incidence-based mortality rates were assessed using data from the Surveillance, Epidemiology, and End Results database. Joinpoint analyses were used to calculate annual percent changes (APCs) and 95% CIs. Results: Between 2010 and 2019, 66,655 patients, including 34,821 (52.24%) men and 31,834 (47.76%) women, were found to have SBMs, and 57,692 deaths occurred over this period. Lung cancer SBMs, melanoma SBMs, and breast cancer SBMs were ranked in the top three, having the highest age-standardized incidence rates. The incidence of SBMs decreased significantly with an APC of −0.6% from 2010 to 2019, while the APC was 1.2% for lung cancer SBMs, 2.5% for melanoma SBMs, and 0.6% for breast cancer SBMs. The SBM mortality first experienced a rapid increase (APC = 28.6%) from 2010 to 2012 and then showed a significant decline at an APC of −1.8% from 2012 to 2019. Lung cancer SBMs showed similar trends, while melanoma SBM and breast cancer SBM mortality increased continuously. Conclusions: SBMs incidence (2010–2019) and incidence-based mortality (2012–2019) declined significantly. These findings can advance our understanding of the prevalence of SBMs.
format Online
Article
Text
id pubmed-9689090
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96890902022-11-25 Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience Che, Wenqiang Liu, Jie Fu, Tengyue Wang, Xiangyu Lyu, Jun Curr Oncol Article Background: Large epidemiological studies describing the trends in incidence rates and mortality of synchronous brain metastases (SBMs) are lacking. The study aimed to provide a comprehensive understanding of the changes in the incidence and mortality of SBMs over the previous ten years. Methods: Trends in the incidence of solid malignancies outside of the CNS in patients with SBMs and incidence-based mortality rates were assessed using data from the Surveillance, Epidemiology, and End Results database. Joinpoint analyses were used to calculate annual percent changes (APCs) and 95% CIs. Results: Between 2010 and 2019, 66,655 patients, including 34,821 (52.24%) men and 31,834 (47.76%) women, were found to have SBMs, and 57,692 deaths occurred over this period. Lung cancer SBMs, melanoma SBMs, and breast cancer SBMs were ranked in the top three, having the highest age-standardized incidence rates. The incidence of SBMs decreased significantly with an APC of −0.6% from 2010 to 2019, while the APC was 1.2% for lung cancer SBMs, 2.5% for melanoma SBMs, and 0.6% for breast cancer SBMs. The SBM mortality first experienced a rapid increase (APC = 28.6%) from 2010 to 2012 and then showed a significant decline at an APC of −1.8% from 2012 to 2019. Lung cancer SBMs showed similar trends, while melanoma SBM and breast cancer SBM mortality increased continuously. Conclusions: SBMs incidence (2010–2019) and incidence-based mortality (2012–2019) declined significantly. These findings can advance our understanding of the prevalence of SBMs. MDPI 2022-11-02 /pmc/articles/PMC9689090/ /pubmed/36354720 http://dx.doi.org/10.3390/curroncol29110660 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Che, Wenqiang
Liu, Jie
Fu, Tengyue
Wang, Xiangyu
Lyu, Jun
Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience
title Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience
title_full Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience
title_fullStr Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience
title_full_unstemmed Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience
title_short Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience
title_sort recent trends in synchronous brain metastasis incidence and mortality in the united states: ten-year multicenter experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689090/
https://www.ncbi.nlm.nih.gov/pubmed/36354720
http://dx.doi.org/10.3390/curroncol29110660
work_keys_str_mv AT chewenqiang recenttrendsinsynchronousbrainmetastasisincidenceandmortalityintheunitedstatestenyearmulticenterexperience
AT liujie recenttrendsinsynchronousbrainmetastasisincidenceandmortalityintheunitedstatestenyearmulticenterexperience
AT futengyue recenttrendsinsynchronousbrainmetastasisincidenceandmortalityintheunitedstatestenyearmulticenterexperience
AT wangxiangyu recenttrendsinsynchronousbrainmetastasisincidenceandmortalityintheunitedstatestenyearmulticenterexperience
AT lyujun recenttrendsinsynchronousbrainmetastasisincidenceandmortalityintheunitedstatestenyearmulticenterexperience